Unraveling Tau’s Role in Mitochondrial Dysfunction

Inside a healthy nerve cell, mitochondria run a one-way conveyor belt. Electrons move forward, energy accumulates, and a trickle of reactive byproducts gets mopped up before it does any damage. In a diseased one, something throws that belt into reverse, and the trickle becomes a flood.

The culprit, according to a new study in Neuron, is tau: the same protein already blamed for the tangled fibers found in the brains of people with Alzheimer’s disease. Tau has spent decades being cast mainly as a structural protein, an internal scaffold that stabilizes the skeleton of a nerve cell. This study finds it moonlighting somewhere else entirely, and not in a good way.

A conveyor belt running the wrong way

Mitochondria generate energy by passing electrons down a chain of proteins called the electron transport chain, a process that mostly runs forward and produces only small amounts of reactive oxygen species as exhaust. Under certain conditions, though, that chain can run backward instead, a phenomenon called reverse electron transport. Reverse electron transport dumps out far more reactive oxygen species and disrupts the cell’s redox balance, and researchers have already linked tau pathology to mitochondrial dysfunction more broadly, without knowing what, physiologically, was flipping the switch on this particular pathway.

Bingwei Lu, a pathologist at Stanford University who led the study, and his colleagues traced the switch to tau itself, but only once it had been chemically modified through a process called phosphorylation. “This is the first demonstration of exactly what tau does inside mitochondria,” Lu said. “Our discovery of a whole new mechanism driving tauopathies renders these disorders amenable to new therapeutic interventions.”

Working across fruit flies, mice, human brain tissue, and neurons grown from patient stem cells, the team found that phosphorylated tau slips inside mitochondria and binds directly to a protein called NDUFS3, a component of the same electron transport chain machinery. That binding, the researchers showed through several independent lines of evidence including proteinase protection assays and co-immunoprecipitation, is enough to reverse the flow of electrons and switch on the flood of reactive byproducts. “In healthy cells, very little reverse electron transport is happening,” Lu said, which is precisely what made the pathological version so conspicuous once the team went looking for it.

A loop that feeds itself

The relationship runs in both directions, and that’s what makes it dangerous. Reverse electron transport does not just result from hyperphosphorylated tau; it also promotes further tau phosphorylation, at least in part through two kinases called PAR-1/MARK and GSK-3beta. More reverse electron transport activity means more phosphorylated tau available to drive more reverse electron transport. “Once this gets started, it can become self-perpetuating,” Lu said.

To test whether this loop was a cause of tauopathy symptoms rather than merely a byproduct, the researchers turned to genetics and to an experimental drug called CPT that blocks tau from binding NDUFS3 without disrupting the mitochondria’s normal forward-running machinery. Deleting tau altogether, in both flies and mice, blunted reverse electron transport and made the animals notably resistant to heat stress, a trigger known to activate the pathway. CPT produced much the same protection in animals that still had normal tau. In tau-R406W flies bred to develop progressive neurodegeneration, tested in groups of 20 to 50 animals, CPT treatment rescued locomotor decline, extended lifespan, and improved performance on an aversive taste memory test.

The mouse data followed the same pattern at a larger scale. In rTg4510 mice, an established model of tauopathy, several months of daily oral CPT reduced brain atrophy, preserved neurons in the cortex and hippocampus, and improved performance on tests of spatial memory and anxiety-like behavior compared with untreated tauopathy mice. CPT-treated animals also showed less astrocyte and microglial activation and fewer infiltrating immune cells, suggesting the drug curbed neuroinflammation as well as the direct mitochondrial damage. “The main results we observed in our animal models were also seen in patient brain tissues and in the laboratory generated nerve-cell models we derived from tauopathy-patients’ cells,” Lu said. “This suggests that what we learned from this study is applicable to the human nervous system.”

Postmortem brain tissue from people who had progressive supranuclear palsy or Alzheimer’s disease showed the same signature the animal models did: more reactive oxygen species, a shifted NAD+ to NADH ratio, and elevated reverse electron transport activity in isolated mitochondria compared with tissue from people without those diseases. That is a correlation rather than proof that reverse electron transport caused the human disease, since nobody can ethically run the intervention experiment in a living patient’s brain, but it is the kind of correlation that makes a mechanism discovered in mice and flies worth taking seriously in people.

There is a wrinkle worth naming. Lu and a co-author, Su Guo, are co-founders of Cerepeut, the company developing CPT, and both sit on its advisory board. That does not undermine the mitochondrial biology, which rests on independent evidence across four experimental systems, but it is a reason to read the therapeutic framing with a bit more skepticism than the mechanistic findings alone would warrant.

CPT itself remains a laboratory compound. “Much more work remains to be done before it can undergo clinical trials,” Lu said, and the authors are careful to note that whether other tau mutations linked to frontotemporal dementia drive reverse electron transport the same way is still untested. Reverse electron transport has also been implicated in aging and in diseases well beyond tauopathies, which raises a broader possibility: that a process nobody thought much about, running in the wrong direction inside cells under stress, turns out to matter for a lot more than one misfolded protein.

Frequently Asked Questions

What is reverse electron transport?

Reverse electron transport is what happens when the electron transport chain inside mitochondria runs backward instead of forward. Instead of the small amount of reactive byproduct produced by normal, forward-running energy production, the reversed flow generates a much larger burst of reactive oxygen species and shifts the cell’s redox balance. It occurs at low levels under normal conditions but becomes much more active under stress or in disease.

Does this mean Alzheimer’s is caused by mitochondria rather than tau tangles?

Not exactly. The study does not replace the existing tangle-based picture of tau pathology; it adds a separate pathway that runs independently of tangle formation. Hyperphosphorylated tau appears to damage nerve cells partly by disrupting mitochondrial energy production, in addition to whatever role tangles themselves play.

Could this discovery lead to a new Alzheimer’s treatment?

This discovery could eventually inform new treatments, but that is still a distant prospect. The experimental compound CPT blocked the pathological process and improved outcomes in flies and mice, but it has not been tested in humans and has not entered clinical trials.

Why does the fly and mouse research matter if it was not done in people?

The fly and mouse research matters because the same mitochondrial signature the researchers found in animals also turned up in postmortem brain tissue from human patients with Alzheimer’s disease and progressive supranuclear palsy. That does not prove the mechanism causes human disease, since the human comparison is observational rather than an intervention, but it strengthens the case that the animal findings are relevant to people.

Is there a conflict of interest in this research?

Yes, there is a disclosed conflict of interest: the study’s senior author and a co-author are co-founders of the company developing the experimental drug CPT as a therapeutic. That financial interest does not itself invalidate the mitochondrial findings, which are supported by independent evidence across four experimental systems, but it is a reason to treat the therapeutic framing with some added caution.